J Cancer 2021; 12(15):4505-4512. doi:10.7150/jca.57831

Review

Prognostic and Therapeutic Significance of BTN3A Proteins in Tumors

Sihan Chen1,2#, Zhangyun Li1#, Wenyi Huang1, Yanyan Wang3✉, Shaohua Fan1✉

1. School of Life Science, Jiangsu Normal University, Xuzhou, Jiangsu, China.
2. College of Health Science, Jiangsu Normal University, Xuzhou, Jiangsu, China.
3. Department of Ultrasonic Medicine, Xuzhou First People's Hospital, Jiangsu, China.
# These authors contributed equally to this work.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Chen S, Li Z, Huang W, Wang Y, Fan S. Prognostic and Therapeutic Significance of BTN3A Proteins in Tumors. J Cancer 2021; 12(15):4505-4512. doi:10.7150/jca.57831. Available from https://www.jcancer.org/v12p4505.htm

File import instruction

Abstract

The Butyrophilin 3A (BTN3A) family is a type I transmembrane protein belonging to the immunoglobulin (Ig) superfamily. The family contains three members: BTN3A1, BTN3A2 and BTN3A3, which share 95% homology in the extracellular domain. The expression of BTN3A family members is different in different types of tumors, which plays an important role in tumor prognosis. Among them, there are many studies on tumor immunity of BTN3A1, which shows that it is essential for the activation of Vγ9Vδ2 T cells, while BTN3A3 is expected to become a potential therapeutic target for breast cancer. Recent studies have shown that the BTN3A family is closely related to the occurrence and development of tumors. Now the BTN3A family has become one of the research hotspots and is expected to become new tumor prediction and treatment targets.

Keywords: Butyrophilin 3A, Tumor, Prognosis